A gene therapy that patients breathe in has been found to shrink lung tumours by inserting immune-boosting genes into ...
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...
Interesting Engineering on MSN
First-ever experimental gene therapy seeks to restore vision by rejuvenating eye neurons
Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene ...
Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...
As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...
News Medical on MSN
First topical CRISPR gene therapy corrects disease-causing mutations in human skin
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the University of British Columbia are extending those possibilities to the skin for ...
FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...
The Food and Drug Administration paused trials for two experimental gene therapies from Regenxbio after one child developed a brain tumor, the company announced Wednesday.
MedPage Today on MSN
Gene therapy shows signs of delayed progression in fatal neurodegenerative disease
All participants had adverse events, but most were moderate in severity ...
Feb 9 (Reuters) - Regenxbio said on Monday the U.S. Food and Drug Administration had declined to approve its gene therapy for ...
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results